Gilead Sciences Inc. (GILD) is seeing a significant rise in its stock price, reflecting positive investor sentiment.
Today, Gilead's stock climbed by 2.38%, closing at CA$147.66. This increase comes alongside strategic collaborations and favorable market movements in the biotechnology sector.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$187.44B
Div. yield
2.19%
Div. / share
$3.22
52W high
$154.51
52W low
$111.27
1W change
+4.01%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 12, 2026
Wall Street analysts forecast GILD stock price to rise 423.8% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.38
+423.8% Upside
Previously C$159.27 on Oct 9, 2026
Current Price
C$30.43
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
20.8%
Annualized
90-Day Vol
27.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$179.84
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$159.66 | C$148.59 – C$171.54 |
| 60 trading days | C$169.45 | C$153.08 – C$187.56 |
| 90 trading days | C$179.84 | C$158.80 – C$203.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider Gilead's recent collaborations and its growth potential in oncology as indicators of a positive outlook for the company.
Gilead's stock rises 2.38%
The increase in Gilead's stock price today shows investor optimism amid ongoing strategic collaborations.
Bull case
Gilead's extended collaboration with Nurix Therapeutics suggests strong potential for new oncology treatments, which could boost future revenue growth.
Bear case
Despite today's gains, Gilead's recent performance has been volatile, and upcoming earnings reports might highlight challenges in maintaining profitability.
Positive Collaborations Fuel Growth
Advertisement
Gilead's recent partnership with Nurix Therapeutics has been extended, allowing further development of oncology programs. This collaboration is expected to produce innovative treatments, strengthening Gilead's position in the competitive biotech landscape.
Market Trends and Performance
The overall market is showing positive trends, with Gilead's stock benefiting from a broader rise in the biotechnology sector. Investors remain optimistic as Gilead prepares for its upcoming earnings report, which could shed light on its financial health.
Looking Ahead
As Gilead navigates its strategic partnerships and market dynamics, investors will closely watch the upcoming earnings disclosures to assess the company's future performance and profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
